IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

• Drug: IBI334 D
• Drug: IBI334 C
• Drug: IBI334 A
• Drug: IBI334 B
• Drug: IBI334 F
• Drug: IBI334 E

Inclusion Criteria：

1. Male or female subjects ≥ 18 years old;
2. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1;
3. Anticipated life expectancy of ≥ 12 weeks;
4. Adequate bone marrowsoft, spongy tissue found in bones that makes blood cells and organ function;Criteria for dose escalation phase only:
5. Has a documented (histologically- or cytologically-proven), unresectable, locally advancedat a late stage, far along or metastatic solid tumor that is refractory to or intolerable with standard treatment, or for which no standard treatment is available (mainly focused on non-small-cell lung cancer, head and neck squamous cell carcinomacancer arising from tissues that line organs and RAS-wildtype colorectal cancer);
6. At least 1 evaluable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1;Criteria for dose expansion phase only:
7. Has a documented (histologically- or cytologically-proven), unresectable, locally advanced or metastatic non-small-cell lung cancer, head and neck squamous cell carcinoma or RAS-wildtype colorectal cancer that is refractory to or intolerable with standard treatment, or for which no standard treatment is available;
8. At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.